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Adriamycin-Incluced nephropathy as a model of chronic progressive
glomerular disease. Serial changes in urine protein, blood chemistry,
and histology of the kidney were investigated in rats for 28 weeks after
injections of adriamycin (ADR). Massive proteinuria, hypoalbumin-
emia, and hyperlipidemia were observed at week 4 and throughout the
experiment. Both BUN and serum creatinine began to increase at week
16 and reached the uremic level at week 28, Light microscopic study of
the kidney demonstrated a normal appearance at week 4, vacuole
formation in glomerular tuft at weeks 8 and 12, focal and segmental
glomerular sclerosis at weeks 16 and 20, and extensive glomerular
sclerosis with tubulointerstitial degenerations at weeks 24 and 28.
Immunohistologically, 1gM with a small amount of IgG and C3 appeared
in the scierosing glomeruli from week 16. Aggregated human IgG,
injected intravenously at week 24, had accumulated mainly in the
glomeruli. Electron microscopy revealed degenerative changes of
glomerular epithelial cells with small vacuoles in the cytoplasm at week
4. Size of vacuoles increased at the later stage. In conclusion, ADR
produced chronic, progressive glomerular changes in rats, which led to
terminal renal failure. The segmental glomerular sclerosis and 1gM-
dominant glomerular deposition in these animals are similar to patho-
logical characteristics of focal and segmental glomerular sclerosis seen
clinically.
Adriamycin (ADR) is a commonly used antineoplastic anti-
biotic that damages renewal systems of highly proliferative cells
such as the epithelium of the intestinal tract and cell hemato-
poietic organs. In addition, it has nephrotoxic actions in exper-
imental animals [1—3]. In short-term observations, heavy pro-
teinuria associated with loss of glomerular polyanion, focal
fusion of foot processes, and swelling, as well as vacuolation of
epithelial cells, have been evidenced in ADR-treated rats [4, 5],
in which nephrotic signs are manifest yet their renal function is
preserved. In contrast, a long-term study demonstrated severe
renal damage such as extensive glomerular lesions, tubular
dilatation, and stromal fibrosis [61. These observations indicate
that the ADR-induced nephropathy have chronicity and a
self-perpetuating property, which are characteristic features of
chronic progressive renal disease in humans [71.However, little
is known of the self-perpetuating mechanism leading to terminal
renal failure in chronic renal diseases. We now report details on
long-term observations of rats with ADR-induced nephropathy.
Methods
Experimental Design
The experiments were performed on adult, male Lewis rats,
8 weeks old and weighing 250 to 300 g (Charles River Breeding,
Tokyo, Japan). The rats were fed a regular diet containing 0.3%
NaC1 and 22.0% protein. Adriamycin (2 mg/kg) was intrave-
nously administered to 70 rats twice at a 20-day interval. This
schedule was determined in preliminary experiments in which
we evaluated the dosage interval to produce definite renal
lesions without acute toxicity in all the rats used. Body wt,
blood pressure, hematocrit, urinary protein, serum albumin,
cholesterol, BUN, and serum creatinine were checked every 4
weeks after the second injection of ADR until week 28. Seven
animals were sacrificed every 4 weeks for histological study.
Forty rats were used for a control study in which isotonic saline
was given instead of ADR, and the animals were sacrificed
every 8 weeks until week 24; the final study was done at week
Blood pressure measurement
Systolic blood pressure was measured in the conscious rats
every 4 weeks by the tail cuff method. The animals were
warmed for 10 mm at 37°C before the measurement.
Analytic methods
Twenty-four-hr urine specimens were collected. Urinary
protein was measured using the sulfosalycylic acid method [8].
Blood samples were obtained via percutaneous puncture of the
tail artery. Serum protein was measured by the method of
Lowry et al [9], and the protein fraction was analyzed
electrophoretically. BUN was measured by the urease
indophenol method, and serum creatinine by kinetic creatinine
assay. Serum cholesterol was determined by an enzymatic
method [10].
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Renal histological examination
Kidneys were fixed in 10% neutral buffered formalin and
embedded in paraffin for light microscopic study. Sections 2 m
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thick were stained with hematoxylin and eosin (H&E), periodic
acid-Schiff reagent (PAS), or phosphotungstic acid hematoxy-
lin. Histological evaluation was made independently by two
pathologists without prior knowledge of the experimental
groups. A semiquantitative score was used to evaluate the
degree of glomerular sclerosis, according to the method of Raij,
Azar, and Keane [11]. A minimum of 20 glomeruli (range, 20 to
60) in cortical and juxtamedullary portions was examined
independently, and the severity of the lesion was graded from 0
to 4+ according to the percentage of glomerular sclerosis.
Thus, a 1+ lesion represented an involvement of 25% of the
glomerulus, while a 4+ lesion indicated that 100% of the
glomerulus was involved. An injury score was then obtained by
multiplying the degree of damage (0 to 4+) by the percentage of
the glomeruli with the same degree of injury, that is, increase in
mesangial material or glomerular sclerosis. The extent of the
injury for each individual tissue specimen was then obtained by
the addition of these scores. For example, ifS of 20 glomeruli
had a lesion of 1 + and 5 of 20 had a lesion of 3+, the final injury
score for that specimen would be: ((1 X 5/20) + (3 X 5/20)) X
100 100.
For immunohistological studies, fresh kidney specimens
were snap-frozen at —70°C in a dry ice-acetone mixture and
sectioned with a cryostat microtome. Sections 4 m thick were
exposed to fluorescein isothiocyanate (FITC) conjugated anti-
rat 1gM, IgG, or C3 goat serum (Cappel Lab., Cochranville,
Pennsylvania, USA) for 1 hr at 37°C. The sections were
examined under a fluorescence microscope (Carl Zeiss, Inc.,
New York, New York, USA). At the 24th week, aggregated
human IgG (AHIgG, 40 mg/100 g) was injected intravenously to
seven rats in both ADR-treated and control groups, and, 12 hr
later, these rats were sacrificed. AHIgG was prepared by
heating human y-globulin (Midori-Juji Corp., Osaka, Japan) at
63°C for 15 mm [121. The sections were stained with FITC-
conjugated anti-human IgG goat serum.
For electron microscopy, kidney specimens were fixed in 1.4%
glutaraldehyde buffered with 0.1 M cacodylate, postfixed in ice-
cold 1% osmium tetroxide in the same buffer for 2 hr, dehydrated
in a graded series of ethanol, and embedded in Epon 812. Ultrathin
sections were stained with uranyl acetate and lead citrate and
examined under a JEM-100S electron microscope (Nihon-Denshi
Corp., Tokyo, Japan).
Statistical analysis
Student's t test was used for statistics. Data were expressed
by mean SD.
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Fig. 1. The courses of A body wt, B hematocrit, C systolic blood pressure, and D urinary protein in ADR-admimstered rats (•—•) and control
rats (0—0). Values are the mean of ten rats SD. *P < 0.001, *p < < 0.01 compared with the controls.
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Results
None of the ADR-treated rats showed acute toxicities such as
severe anemia, gastrointestinal bleeding, and cachexia in an
early period. Body wt was increased to a lesser extent in the
ADR-treated rats than in control rats during the observation
(Fig. lA). In the ADR-treated rats, hematocrit began to de-
crease at week 16, and some of the rats were severely anemic
by the end of the experiment (Fig. 1B). Blood pressure started
to rise at week 8 and remained high thereafter (Fig. 1C).
Urinary protein was positive shortly after the second ADR
injection, and the amount excreted progressively increased and
reached the level of 969.1 122.6 mg/day at week 12 (Fig. lD).
Significant decrease of serum albumin with marked increase in
cholesterol was observed at week 8 and continued throughout
the experiment (Figs. 2A and B). Renal function was fairly well
preserved until week 16, when both BUN and serum creatinine
began to increase (Figs. 2C and D). BUN increased significantly
at week 24 or later, compared with the controls, and serum
creatinine also showed the same tendency at week 16 or later.
Uremic manifestations such as marked azotemia, anemia,
cachexia, and convulsion were observed in most of ADR-
treated rats at week 28, at which time three animals died.
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Kidney wt gradually increased, reached a peak at week 20,
and then slightly decreased (Fig. 3). Enlarged kidneys were
granular on the surface and pale in color. Light microscopic
examinations revealed that glomeruli and tubulointerstitium
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Fig. 2. The courses of A serum albumin, B cholesterol, C BUN, and D serum creatinine in ADR-administered rats (•—•) and control rats
(0—0). Values are mean of ten rats SD. *p < 0.001, < 0.005 compared with controls.
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Fig. 3. Kidney wt (mean of right and left kidneys) in ADR-administered
rats (—•) and control rats (0—0). Values are mean of seven rats
SD. *D < 0.001 compared with the controls.
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Fig. 4. A Glomerulus of ADR-administered rats at week 4 showing no
significant glomerular alteration. B Glomerulus at week 8 showing several
vacuoles. C Glomerulus at week 16 showing segmental sclerosis (—) and
vacuole. D Glomerulus at week 24 showing advanced sclerosis with
hyalinosis in most capillary lumens. E Tubulointerstitium at week 28
showing tubular dilatation with proteinaceous cast and interstitial fibrosis
and cell infiltration. (PAS stain, Fig. 4A x420, B x390, C x390, D x360,
E x120)
were fairly intact at week 4 (Fig. 4A). At weeks 8 and 12,
several vacuoles were seen in some glomenili (Fig 4B), the
diameter of which was almost twice as large as that of the
capillary lumen. At week 8, less than 10% of all glomeruli
contained the vacuoles while more than 30% did so at week 12.
Segmental glomerular sclerosis appeared in some glomeruli at
week 16 (Fig. 4C) and 20. At weeks 24 and 28, extensive
glomerular sclerosis, tubular dilatation, dense proteinaceous
casts, and interstitial fibrosis with round cell infiltration were
observed in most of the ADR-treated rats (Figs. 4D and E).
Small arteries and arterioles showed no remarkable changes. In
the capillary lumen of the sclerosing glomeruli, fibrin deposition
was occasionally present. Figure 5 shows the degree of glomer-
ular sclerosis in cortical and juxtamedullary portions of the
Fig. 6. Glomerulus stained with FITC-anti-rat 1gM in ADR-adminis.
tered rats at week 20 showing segmental distribution of 1gM, (x380)
kidney. There were no differences in the glomerular lesions
between both areas.
Immunofluorescence microscopic studies showed no deposi-
tions of 1gM, IgG, or C3 until week 12. From week 16, 1gM was
present in some glomeruli, in segmental or global distribution
(Fig. 6), and corresponded to the sclerosing area of glomeruli
determined by light microscopy. IgG and C3 were also present
in a similar pattern, but in a lesser intensity. Table 1 shows the
degree of glomerular deposits for 1gM, IgG, and C3 in all the rats
studied. the number of rats with intense deposits of 1gM
increased at the later stage of the observation. A similar
tendency was observed in case of deposition of IgG or C3.
Glomerular staining for human IgO after the injection of AHIgG
was intense and diffuse in the ADR-treated rats (Fig. 7), but was
not observed in the control rats.
Electron microscopic studies revealed degenerative changes
in the epithelial cells in the ADR-treated rats. Some visceral and
panetal epithelial cells had enriched cellular organelles, and
small vacuoles were seen in the cytoplasm at weeks 4 and 8
(Fig. 8). The origin of the vacuoles could not be determined
precisely, but it seemed that the vacuole arose in a dilated
endoplasmic reticulum. The endothelial and mesangial cells
showed no significant alteration at these stages. Large oval or
spherical vacuoles were prominent at weeks 12 and 16.
Vacuoles in the epithelium increased in number and in size.
There was widespread fusion of foot processes as well as
increased osmiophilic substance in the cytoplasm adjacent to
the glomerular basement membrane (GBM) at week 16 (Fig. 9).
Large vacuoles surrounded by thin epithelial cytoplasm were
often seen to occupy the urinary space at weeks 20, 24, and 28
(Fig. 10). Sclerotic changes of capillary loops began to appear at
week 12. The sclerotic area consisted of mesangial cell prolif-
eration, increased mesangial matrix, deposition of hyaline sub-
stances, and lipid-containing cells.
Discussion
In ADR-treated rats, urinary protein appeared shortly after
intravenous injection of ADR and increased progressively with
time. Furthermore, pathological changes of the kidney devel-
oped during long-term observation, and the course resembled
that seen in chronic renal diseases in humans. In addition,
histological changes such as focal and segmental glomerular
sclerosis and 1gM-dominant deposition in glomeruli also indi-
cate that this nephropathy is similar to focal and segmental
glomerular sclerosis (FGS) seen clinically. FGS-like chronic
renal disease has been produced by repeated injection with
aminonucleoside (AMNS) in rats [13, 14], in which vacuolated
glomerular epithelial cells, capillary collapse, and progressive
hyalinization are major histological findings. These are very
similar to the findings in ADR-treated rats. However, frequent
and continuous administration of AMNS is necessary to main-
tain urinary protein excretion and for renal lesions to develop in
rats. In contrast, administration of ADR led to progressive renal
lesions without additional administrations for 28 weeks after
two intravenous injections, and terminal renal failure occurred.
Bertani et al gave a single injection of ADR (5 mglkg) and noted
after 6 months a focal glomerular sclerosis associated with
severe tubular and interstitial changes in 50% of the biopsied
specimens [151. These results indicate that the renal lesions of
ADR nephropathy are more self perpetuating than those in the
AMNS-treated rats.
Many nephrotoxic drugs have acute effects that may cause
acute tubular necrosis, but ADR differs as it has chronic effects
on the kidney, as shown in this study. The initial renal lesion
induced by ADR may have an essential property to relate with
progressive renal destruction. Various immunological or hemo-
dynamic changes caused by ADR may play a role in the
chronicity of ADR-induced nephropathy.
The renal lesions in ADR-treated rats varied with the stages:
fairly normal appearances at the early stage, vacuolated
changes in glomeruli at the middle stage, and either segmental
or global sclerosis with tubulointerstitial changes at the late
stage. These findings are compatible with previous observa-
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Fig. S. Degree of glomerular sclerosis in cortical portion (•—•) and
juxtamedullarv portion (•—I) ofADR-administered rats and cortical
portion (0—0) andjuxtamedullary portion (LI—Li) of control rats. The
values are semiquantitative scores to evaluate the degree of glomerular
sclerosis, according to the method of Raij et al [11] and mean of seven
rats SD.
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Table 1. Immunohistological findings in ADR-administered rats"
Time after ADR
administration
week
1gM IgG C3
— + ++ +++ — + -f--I- ++-I- — + ++ +++
0 7 0 0 0 7 0 0 0 7 0 0 0
4 7 0 0 0 7 0 0 0 7 0 0 0
8 7 0 0 0 7 0 0 0 7 0 0 0
12 7 0 0 0 7 0 0 0 7 0 0 0
16 1 3 3 0 3 4 0 0 4 3 0 0
20 0 2 2 3 0 5 2 0 0 5 2 0
24 0 2 1 4 0 3 4 0 0 6 1 0
28 0 2 1 4 0 3 4 0 0 5 2 0
a Seven animals were studied every 4 weeks.
Symbols are: —, negative; +, weak; ++, moderate; +++, intense.
Fig. 7. Glomerulus stained with FITC-antihuman IgG in ADR-adminis-
tered rats at week 24, 12 hr after AHIgG administration, showing
increased deposition of AHIgG. (x380)
tions: the minimal alterations at week 4 seen by Bertani eta! [4];
vacuolation and swelling of epithelial cells at week 8 reported
by Weening and Rennke [5]; and glomerular sclerosis and
stromal fibrosis at week 29 as noted by Fajardo et a! [6]. In the
present study, electron microscopy revealed small vacuoles in
the cytoplasm of epithelial cells and focal fusion of the foot
processes, even at the early stage. These vacuoles became
larger and increased in number at the later stage. These findings
indicate that the epithelial vacuolation is an initial lesion in the
kidney and progresses into an irreversible state. The epithelial
degeneration may play an important role in the progress of
glomerular deterioration. Ryan et al suggested that segmental
changes of FGS in human and animal models are well explained
by differing degrees of epithelial cell injury leading to specific
segmental area of denuded glomerular basement membrane [16,
17]. Epithelial cells retain glomerular function by producing
GBM or by acting as a filtration barrier in association with the
endothelium and GBM. Severe epithelial injury increases the
transcapillary flux of macromolecules. The elevated transglo-
merular traffic may cause an intraglomerular accumulation of
the macromolecules, which ultimately increases the matrices in
the mesangial area. An overloading of the mesangial region
leads to an increase in matrix deposition and to a glomerular
sclerosis. Indeed, the elevated uptake of AHIgG found in the
glomeruli indicates an increased glomerular accumulation of the
macromolecules in ADR-treated rats.
The antineoplastic effect of ADR at the cellular level is an
inhibition of RNA synthesis by drug binding to DNA [181.
Giroux et al reported that DNA-bound ADR was less nephro-
toxic than free ADR [19], thereby indicating that the renal
lesions in ADR-treated rats are directly related to pharmaco-
logical effects. Another mechanism of tissue damage from ADR
is the formation of toxic oxygen [20]. This mechanism may
become important in light of the observation that glomerular
injury and glomerular permeability in nephrotoxic serum
nephritis is related to the formation of oxygen free radicals [21].
In humans, however, consistent ADR nephrotoxicity is not
evident, in contrast to animals. Species-related variations in
toxicity of anthracycline have been noted in the kidney and
heart [22]. Unique long-term toxic effects on kidneys have been
observed only in rats and rabbits, while effects on the heart
were noted in humans, rabbits, monkeys, and hamsters [2].
1gM, IgG, and C3 were observed in glomeruli of ADR-treated
rats at the late stage. On the other hand, none of the previous
reports has demonstrated a positive immunofluorescence in
ADR-treated rats [4, 5,7]. This discrepancy is probably due to
length of the observation period from ADR administration to
death. Those studies were completed within 10 weeks at the
longest, a time when no positive immunohistology was seen in
our study.
The deposition of immunoglobulin and complement raises the
question of whether immunological mechanisms may contribute
to renal deterioration in ADR-treated rats. Verosa, Miller, and
Michael noted deposition of immunoglobulin and complement
in glomeruli undergoing sclerosis and suggested that immuno-
logical mechanisms may participate in the progression of
glomerular injury, regardless of the primary disease [23]. How-
ever, the immune deposition in ADR-treated rats was 1gM
dominant and was located on the sclerosing area of glomeruli
late in the course. An elevated uptake of AHIgG was found in
the same area. Further, electron microscopic examination
revealed no electron dense deposits that would suggest im-
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Fig. 8. Glomerulus in an ADR -administered rat at week 8. The podocyte has small vacuoles, probably originating from the endoplasmic reticulum.
The mesangial and endothelial cells show no remarkable changes. (x9200)
Fig. 9. Glomerulus in an ADR-administered rat at week 16. There are widespread fusion and increased osmiophilic substances (—) in the cytoplasm
adjacent to the GBM. The parietal epithelial cell also shows vacuolar degeneration. Abbreviation: CBM, capsular basement membrane. (x7650)
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Fig. 10. Glomerulus in ADR -administered rat at week 28. The podocyte is ballooned up by large vacuoles which are separated by a veil of thin
cytoplasm. In the empty spaces, fibrin strands (—) are evident. (x9100)
mune-complex deposition. These findings indicate that the
glomerular capillary wall undergoing sclerosis is open to
glomerular perfusion and large-size protein accumulates in
these areas. Thus, the deposition of immunoglobulin may be an
effect of prior damage rather than a mechanism related to
glomerular damage.
Hypertension may aggravate renal deterioration in ADR-treated
rats, although it was too mild to cause hypertensive vascular
lesions. Superimposed hypertension has been reported to be an
accelerating factor in glomerular sclerosis [24, 25]. Diseased
kidneys are susceptible to hemodynamic changes caused by
hypertension [26]. Bristow et al reported that intravenous ADR
caused cardiac and peripheral vascular hemodynamic abnormali-
ties associated with an increased release of histamine and cate-
cholamine into the circulation, and that histamine antagonists and
adrenergic blockers prevented the renal lesions [27]. This report is
pertinent to recent observations in which hemodynamic changes
in the glomerulus were found to be linked to focal and segmental
glomerular sclerosis [28, 29]. Further investigations are necessary
to clarify the mechanisms related to hypertension and the contri-
bution to the renal deterioration.
In conclusion, in the ADR-treated rats, there was a chronic
progressive renal deterioration during a long observation. Al-
though the cause of this nephropathy differed from that in cases
of chronic renal disease seen clinically, both show similarities
with regard to the progress of renal deterioration. Thus, this
model should be useful for the study of chronic glomerular
disease.
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